Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AMT-253
- Development stage
- Unknown
- Lead developer
- Multitude Therapeutics
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
AMT-253 is a first-in-class antibody-drug conjugate (ADC) designed to target MUC18 (also known as Melanoma Cell Adhesion Molecule, MCAM, or CD146), a cell surface glycoprotein overexpressed in various solid tumors. Developed by Multitude Therapeutics, the drug consists of a humanized IgG1 antibody with high affinity for MUC18 conjugated to exatecan, a potent topoisomerase I (TOP1) inhibitor. The conjugation utilizes a proprietary protease-cleavable self-immolative T moiety linker with a drug-to-antibody ratio (DAR) of 8. AMT-253 is currently being evaluated in Phase 1/2 clinical trials for the treatment of advanced solid tumors, specifically focusing on melanoma and gynecologic cancers such as ovarian, cervical, and endometrial cancers. It has demonstrated promising antitumor activity and a manageable safety profile in early-stage clinical settings.
- Other names
- MUC18-ADCMUC-18-ADCMUC 18-ADC
02
Targets
MCAMTOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on AMT-253.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AMT-253.